SR9009 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-17. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Ether solutions of up to 50 mol% dichloroacetylene are relatively stable, and such solutions can be safely generated by the dehydrochlorination of trichloroethylene. A popular procedure uses potassium hydride as the base:
The Financial Times wrote that the strikes were intended to pressure members of the Venezuelan government into resigning or arranging a handover of power by demonstrating the US military's capability to capture or kill them through targeted strikes. According to The New York Times, "specialists in the laws of war and executive power" stated that Trump had "used the military in a way that had no clear legal precedent or basis". In an interview with Vanity Fair magazine, Susie Wiles, Trump's White House Chief of Staff, told journalist Chris Whipple that Trump would "keep on blowing boats up until Maduro cries uncle." Whipple himself believed the terminology spoke to the possibility of Trump wanting to see regime change, and Wiles described the Vanity Fair article as "a hit piece".
=== Commercial applications === According to a 2010 survey, the three primary uses of the 26,000 low-energy particle accelerators operating worldwide are radiotherapy (44%), ion implantation (41%), and industrial processing (9%). HVEC made foundational contributions to all three. The company's compact Van de Graaff generators were among the first artificial radiation sources commercially available for cancer treatment. Radiation physicist Milford Schulz called them "truly milestones in the progress of radiotherapy." The first medical linear accelerator—now the dominant technology in cancer treatment—was assembled at Stanford using a retrofitted HVEC machine. Ion implantation, pioneered at HVEC's Ion Physics Corporation, became standard practice in semiconductor manufacturing by the late 1970s. The technique enabled MOS integrated circuits that dominate modern electronics. Radiation crosslinking, developed at Electronized Chemicals Corporation, produced heat-shrink tubing and films now ubiquitous in electrical wiring and food packaging.
== Governance == The South African Government department most related to the country's logistics sector is the Department of Transport (DoT). In 2023, the DoT released a Roadmap for the Freight Logistics System in South Africa. In the document, the government outlined that while it believed that strategic infrastructure such as rail and ports would remain publicly-owned, as it belongs to the people of South Africa, operating of such infrastructure could be opened up to private investment. Doing so, the government believes, will allow for increased efficiencies and competitiveness. The roadmap serves as a guide for state-owned transit company Transnet to achieve this balance, translating policy commitments into actions that are to be taken by the entity. In 2025, one of the themes of the Department of Transport's budget was facilitating the development of the country's air cargo capacity. Part of a R21.7-billion Airports Company South Africa (ACSA) infrastructure development allocation was set aside for increasing air freight handling through its network of airports. South Africa's fuel pipelines are regulated by the National Energy Regulator of South Africa (NERSA).
Sources: en.wikipedia.org
The Wallerian degeneration pathway has been further illuminated by the discovery that sterile alpha and TIR motif containing 1 (SARM1) protein plays a central role in the Wallerian degeneration pathway. The gene was first identified in a Drosophila melanogaster mutagenesis screen, and subsequently knockouts of its homologue in mice showed robust protection of transected axons comparable to that of WldS. SARM1 catalyzes the synthesis and hydrolysis of cyclic ADP-ribose (cADPR) from NAD+ to ADP-ribose. SARM1 activation locally triggers a rapid collapse of NAD+ levels in the distal section of the injured axon, which then undergoes degeneration. This collapse in NAD+ levels was later shown to be due to SARM1's TIR domain having intrinsic NAD+ cleavage activity. The SARM1 protein has four domains, a mitochondrial localization signal, an auto-inhibitory N-terminus region consisting of armadillo/HEAT motifs, two sterile alpha motifs responsible for multimerization, and a C-terminus Toll/Interleukin-1 receptor that possesses enzymatic activity. Activation of SARM1 is sufficient to collapse NAD+ levels and initiate the Wallerian degeneration pathway. The activity of SARM1 helps to explain the protective nature of the survival factor NMNAT2, as NMNAT enzymes have been shown to prevent SARM1-mediated depletion of NAD+. This relationship is further supported by the fact that mice lacking NMNAT2, which are normally not viable, are completely rescued by SARM1 deletion, placing NMNAT2 activity upstream of SARM1.
tropism Also tropic movement. The directional growth or movement of a cell or organism in response to a stimulus, e.g. light, heat, the pull of gravity, or the presence of a particular chemical, such that the response is dependent on the direction of the stimulus (as opposed to a non-directional nastic response). Positive tropism is growth or movement toward the stimulus; negative tropism is away from the stimulus. See also taxis and kinesis.
== Growth hormone deficiency == In a study of children with growth hormone deficiency, ibutamoren performed better than other growth hormone secretagogues at improving growth hormone levels. An ongoing study compares ibutamoren directly to injectable hGH in terms of height velocity in this population. Topline data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD met all primary and secondary endpoints.
== Leadership == The Ethiopian People's Revolutionary Democratic Front (EPRDF) was a coalition of various ethnically-based political movement created by the Tigray People's Liberation Front (TPLF), a guerrilla movement formed in the contemporary Tigray region of northern Ethiopia in 1975. The TPLF was at the core of the EPRDF, although other political movements in the coalition included the Ethiopian People's Democratic Movement (which later became the Amhara National Democratic Movement, representing those from what is now known as the Amhara region of the country) and the Oromo People's Democratic Organisation (OPDO), representing those from the Oromia region of Ethiopia. 1992 marked the first elections of the transitional period, which were held to select representatives for 14 new regional assemblies. The main political movements competing for power were the EPRDF, the All Amhara People's Organisation, and the Oromo Liberation Front (OLF). During the campaign cycle, various opposition movements (including the OLF) publicly withdrew from the races, complaining that the threats and intimidation tactics allegedly used by the EPRDF would make it impossible for the elections to be free and fair.
=== Metal binding === Metallothionein has been documented to bind a wide range of metals including cadmium, lead, zinc, mercury, copper, arsenic, silver, etc. Metalation of MT was previously reported to occur cooperatively but recent reports have provided strong evidence that metal-binding occurs via a sequential, noncooperative mechanism. The observation of partially metalated MT (that is, having some free metal binding capacity) suggest that these species are biologically important. Metallothioneins likely participate in the uptake, transport, and regulation of zinc in biological systems. Mammalian MT binds three Zn(II) ions in its beta domain and four in the alpha domain. Cysteine is a sulfur-containing amino acid, hence the name "-thionein". However, the participation of inorganic sulfide and chloride ions has been proposed for some MT forms. In some MTs, mostly bacterial, histidine participates in zinc binding. By binding and releasing zinc, metallothioneins (MTs) may regulate zinc levels within the body. Zinc, in turn, is a key element for the activation and binding of certain transcription factors through its participation in the zinc finger region of the protein. Metallothionein also carries zinc ions (signals) from one part of the cell to another. When zinc enters a cell, it can be picked up by thionein (which thus becomes "metallothionein") and carried to another part of the cell where it is released to another organelle or protein. In this way thionein and metallothionein becomes a key component of the zinc signaling system in cells.
Sources: en.wikipedia.org
== Intervention strategies == Aβ is the main component of the kind of amyloid plaques that form in the brains of people with Alzheimer's disease. Aβ can also form the deposits that line cerebral blood vessels in cerebral amyloid angiopathy. The plaques are composed of aggregated Aβ oligomers called amyloid fibrils, a protein fold shared by other peptides such as the prions associated with protein misfolding disease, also known as proteinopathy.
At nucleotide 1298 of the MTHFR, there are two possibilities: A or C. 1298A (leading to a Glu at amino acid 429) is the most common while 1298C (leading to an Ala substitution at amino acid 429) is less common. 1298AA is the "normal" homozygous, 1298AC the heterozygous, and 1298CC the homozygous for the "variant". In studies of human recombinant MTHFR, the protein encoded by 1298C cannot be distinguished from 1298A in terms of activity, thermolability, FAD release, or the protective effect of 5-methyl-THF. The C mutation does not appear to affect the MTHFR protein. It does not result in thermolabile MTHFR and does not appear to affect homocysteine levels. It does, however, affect the conversion of MTHF to BH4 (tetrahydrobiopterin), an important cofactor in the production of neurotransmitters, and the synthesis of nitric oxide. There has been some commentary on a 'reverse reaction' in which tetrahydrobiopterin (BH4) is produced when 5-methyltetrahydrofolate is converted back into methylenetetrahydrofolate. This however is not universally agreed upon. That reaction is thought to require 5-MTHF and SAMe. An alternative opinion is that 5-MTHF processes peroxynitrite, thereby preserving existing BH4, and that no such 'reverse reaction' occurs. A maternal MTHFR A1298C polymorphism is associated with Down syndrome pregnancy. Subgroup and sensitivity analysis results showed that this polymorphism is a risk factor for Down syndrome pregnancy in Asian populations but not in Caucasian population as well as in overall meta-analysis.
Selank (Russian: Cеланк) is a nootropic anxiolytic peptide based drug developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. Selank is a heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). It is a synthetic analogue of the human tuftsin.
homologous chromosomes Also homologs or homologues. A set of two matching chromosomes, one maternal and one paternal, which pair up with each other inside the nucleus during meiosis. They have the same genes at the same loci, but may have different alleles.
=== Film and television === AAA, la película: sin límite en el tiempo, a 2010 Mexican movie Anbanavan Asaradhavan Adangadhavan, a 2017 Indian Tamil-language movie Associated Argentine Artists (Spanish: Artistas Argentinos Asociados), an Argentine movie distribution company Spearhead from Space, a 1970 Doctor Who serial (production code "AAA")
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.